Results 141 to 150 of about 1,601,842 (182)
Disposition and effects of some non-depolarizing neuromuscular blocking agents in animal and man
, 1976 openaire +1 more source
Neuromuscular blocking agents and reversal agents
Anaesthesia and Intensive Care Medicine, 2005 The neuromuscular blocking agents in routine clinical use may be classed as depolarizing or nondepolarizing. Suxamethonium is the only example of the depolarizing group and is an agonist at the neuromuscular receptor.
Brian J Pollard
exaly +11 more sources
Clinical pharmacology of ORG 7617, a short-acting non-depolarizing neuromuscular blocking agent
European Journal of Clinical Pharmacology, 1994 The dose-response relationship and the time course of action of Org 7617, a short acting non-depolarizing neuromuscular blocking agent, were evaluated during thiopentone, fentanyl, halothane and N2O anaesthesia. Neuromuscular transmission was monitored mechanomyographically. The ED50 and ED90 were calculated after single bolus doses of the drug. Twelve,
Johannes H Proost +2 more
exaly +4 more sources
Theranostics, 2019 Succinylcholine (Sch) is the only depolarizing neuromuscular blocking agent widely used for rapid sequence induction in emergency rooms. Unfortunately, a variety of (sometimes lethal) adverse effects, such as hyperkalemia and cardiac arrest, are associated with its use, and currently there are no specific antidotes to reverse Sch or to treat these side-
Ruibing Wang +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Interactions between ORG9426 and other non-depolarizing neuromuscular blocking agents in ratsin vivo
Journal of Anesthesia, 1992In this study, combined neuromuscular blocking effects of ORG9426 with other non-depolarizing neuromuscular blocking agents were investigated. About 20% steady state neuromuscular block was established by a continuous infusion of one of 6 neuromuscular blocking agents (ORG9426, vecuronium, pancuronium, pipecuronium, d-tubocurarine and metocurine). Then
Kazuhiko Watanabe
exaly +3 more sources
Journal of Clinical Monitoring and Computing, 2020 Succinylcholine is still used in clinical practice. Its duration is highly variable and neuromuscular monitoring is recommended to assess its recovery. Unfortunately, depolarizing neuromuscular block cannot be evaluated by train-of-four (TOF) as no fade ...
Denis Schmartz, Cedric Baumann
exaly +2 more sources
A study in vitro of new short-acting, non-depolarizing neuromuscular blocking agents
Biochemical Pharmacology, 1969Abstract Presently available short-acting, depolarizing myoneural blocking agents have significant side effects such as increased intraocular tension, cardiac arrhythmias desensitization of the postjunctional membrane, skeletal muscle injury and muscle pains. Non-depolarizing blocking drugs do not produce profound blocks of short duration.
Sara Ginsburg, S Ginsburg, R J Kitz
exaly +3 more sources
Two new short-acting non-depolarizing neuromuscular blocking agents
Experientia, 1972Le chlorure de 1,1′-octamethylene et le methylsulfate de 5,5′-octamethylenebis ont chez le chat un effet de blocage neuro-musculaire non depolarisant, de courte duree. Les comparaisons faites avec des analogues voisins suggerent que l'activite de ces composes est influencee par le degre d'empechement sterique autour des atomes d'azote quaternaire.
F C, Copp +4 more
openaire +2 more sources
Depolarizing Neuromuscular Blocking Agents
2017Succinylcholine was first introduced into clinical practice in the 1950s, and is currently the only depolarizing neuromuscular blocker in use. It is unique among the drugs used for muscle relaxation in its rapid onset and short duration of action. These characteristics account for its extensive use in scenarios requiring emergency control of the airway.
Caroline S. Gross, Zhiling Xiong
exaly +2 more sources